On August 1, 2021, Hall, Kevin H.; Brooks, Angelique; Waller, Edmund K. published an article.Recommanded Product: 380843-75-4 The title of the article was Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib. And the article contained the following:
A case of 43-yr-old female was diagnosed with chronic myeloid leukemia in chronic phase (CML-CP) in 2001 when she presented with leukocytosis and a subsequent bone marrow biopsy confirmed the presence of BCR-ABL1 t(9;22) fusion oncogene is reported. As the patient had previously failed all other available TKIs, approval was obtained for use of asciminib through compassionate use. The patient stopped bosutinib and started asciminib 40 mg twice daily based on phase I single agent data in Apr. 2020. Unfortunately, her quant. BCR-ABL1 transcript continued to rise, and bosutinib 500 mg daily was resumed in addition to asciminib in August 2020 when her BCR-ABL1 transcript was 54.6%. Her transcript peaked 2 wk later at 95% but dramatically declined down to 0.1% within 3 mo of starting the combination. She has now continued combination therapy with bosutinib and asciminib for more than 8 mo to date with no discernable side effects. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Recommanded Product: 380843-75-4
The Article related to asciminib bosutinib anticancer combination bcr abl1 chronic myeloid leukemia, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Recommanded Product: 380843-75-4
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics